Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a “Block-and-Lock” Strategy for HIV-1 Treatment

1 Oct 2017

Abstract excerpt

HIV-1 Tat activates viral transcription and limited Tat transactivation correlates with latency establishment. We postulated a "block-and-lock" functional cure approach based on properties of the Tat inhibitor didehydro-Cortistatin A (dCA). HIV-1 transcriptional inhibitors could block ongoing viremia during antiretroviral therapy (ART), locking the HIV promoter in persistent latency. We investigated this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV Research and Treatment
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29045830
DOI: 10.1016/j.celrep.2017.09.080

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a “Block-and-Lock” Strategy for HIV-1 TreatmentPMID 29045830Read ↗

The Block-and-Lock Strategy for Human Immunodeficiency Virus Cure: Lessons Learned from Didehydro–Cortistatin ASemantic proximity Read ↗

Breaking the Silence: Regulation of HIV Transcription and Latency on the Road to a CureSemantic proximity Read ↗

Forging a Functional Cure for HIV: Transcription Regulators and InhibitorsSemantic proximity Read ↗

The Molecular Basis for Human Immunodeficiency Virus LatencySemantic proximity Read ↗

The role of latency reversal in HIV cure strategiesSemantic proximity Read ↗

Curing HIV: Pharmacologic Approaches to Target HIV-1 LatencySemantic proximity Read ↗

HIV latency: experimental systems and molecular modelsSemantic proximity Read ↗

Targeting HIV at its core: A mathematical model for optimizing Tat Inhibitor-based therapies toward enhanced functional cure strategiesSemantic proximity Read ↗

The Current Status of Latency Reversing Agents for HIV-1 RemissionSemantic proximity Read ↗

Mitotic deacetylase complex (MiDAC) recognizes the HIV-1 core promoter to control Tat-activated transcription and latencySemantic proximity Read ↗

Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV CureSemantic proximity Read ↗

Long lasting control of viral rebound with a new drug ABX464 targeting Rev – mediated viral RNA biogenesisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.